Biomarkers for personalized transplantation medicine
====================================================

In 2010, 28,663 transplantations were performed in the United States. Currently, more than 100,000 US patients are waiting for an organ transplant, and each month approximately 4,000 patients are added (Organ Procurement and Transplantation Network data as of April 2011). A significant number of patients on the waiting list are added due to functional failure of a first transplant, reflecting our current inability to ensure long-term allograft function and survival and representing a major problem in transplantation medicine.

The major reason for late allograft loss is chronic allograft damage (CAD), seen as the progressive decline of graft function \> 1 year post-transplantation. The underlying mechanisms of CAD are poorly understood and need to be unraveled if graft function and treatment are to be successful. The definition of valid pre- and post-transplantation biomarkers will facilitate personalized transplantation medicine, leading to long-term graft survival and decreasing numbers of patients on the waiting list.

Identification of biomarkers will aid the understanding of underlying mechanisms by indicating damage early post-transplantation when pathological changes are taking place at the molecular level. This will enable us to better predict the likelihood of an individual\'s allograft survival and assist the development of currently unavailable treatments for CAD. Biomarkers will also allow better matching of donor and recipient and the assessment of an individual\'s risk for graft injury. Current methods for diagnosing graft injury require invasive biopsies and detect pathological changes at advanced and often irreversible stages of allograft damage. The use of more sensitive and specific methodologies based on donor and recipient genotyping, and transcriptional and proteomic profiling to differentiate and detect early stages of organ injury would bridge this gap. This highlights the importance of -omics-based approaches for the improvement of transplant practice.

Nowadays, biomarker studies increasingly integrate information from multiple platforms, such as genotype analyses of single-nucleotide polymorphisms (SNPs), epigenetic studies and analyses of mRNA, microRNA (miRNA), as well as protein, peptide, antibody and metabolite profiling. High-throughput analyses are becoming more accessible, affordable and customizable, and rapid developments in analytical tools now allow integrated meta-analyses of different datasets across different experiments, platforms and technologies \[[@B1]-[@B4]\]. Functional biomarker studies require a discovery and several validation stages, including horizontal and vertical meta-analyses and prospective validation. By this means, several potential biomarkers have been identified. However, advances towards regulatory application, approval and clinical implementation have been slow and costly, partly because of the difficulties faced in externally and prospectively validating these biomarkers.

Here, we concentrate on recent advances made in transplantation biomarker medicine, focusing on the key stages of the biomarker development process. We highlight both laboratory test-based and clinically applied pre- and post-transplantation genomic, transcriptomic and proteomic biomarkers of acute and chronic allograft injury and graft accommodation. We point out the advantages and pitfalls of trying to identify non-invasive blood-based biomarkers and present recent approaches to overcoming related obstacles. Finally, we critically discuss the current status of transplant biomarker research along the road to clinical application.

Identification of clinically relevant biomarkers
================================================

The number of biomarker studies performed so far with respect to solid organ transplantation exceeds 15,000, yet the number of resulting US Food and Drug Administration (FDA) approved biomarker-based diagnostic tests in transplantation stands at two, one being a functional immune assay and the other a non-invasive test based on blood gene expression for predicting the absence of acute allograft rejection (AR) after heart transplantation \[[@B5]\]. Needless to say, the path from discovery and validation of a biomarker in the academic laboratory to its approval for the clinic is torturous. Well-thought-out validation and prospective feasibility studies are needed to move the biomarker discovery process towards FDA application, approval and clinical implementation (Figure [1](#F1){ref-type="fig"}).

![**Outline of the biomarker development process in the US from clinic to bench and back to clinic**. As in drug development, the key phases are the discovery and validation phases, which involve complex FDA-regulated processes. **(a)**High-throughput, often *in silico*technologies are used to discover genomic, transcriptomic, proteomic or integrative investigational biomarkers, which are then **(b)**redefined in several validation phases using independent samples, technologies, and horizontal and vertical meta-analyses. **(c)**A clinically applicable biomarker assay based on good manufacturing practice (GMP) can be developed after prospective studies have confirmed the investigational biomarker. The FDA has to approve clinical studies, and only after successful completion and additional FDA regulation can the biomarker be considered valid and **(d)**be implemented into the clinic.](gm253-1){#F1}

The initial key steps in biomarker development are the discovery phase and the validation phase. In the discovery phase, usually high-throughput technologies on multiple molecular platforms and subsequent biostatistical analyses identify a first biomarker panel, which often comprises several hundreds of candidates. The platforms and molecular techniques used in this phase, such as DNA, RNA, miRNA microarray or antigen-based proto-arrays, usually generate large quantities of data; these methodologies have recently been reviewed by us in detail \[[@B6]\]. Mandatory data deposition in the public domain, such as into the Gene Expression Omnibus (GEO), increasingly allows the use of publicly available data for the biomarker discovery phase and the use of new patient samples for the validation phase. Pathway and network analyses enable integration of experimental data into biological and cellular contexts, and by studying cellular crosstalk and molecular interactions, pathological pathways can be better elucidated \[[@B1]-[@B4]\]. In the near future, data obtained by next-generation sequencing, copy number variation analyses and SNP arrays will be added.

The discovery phase is followed by one, or most frequently, two or three validation phases to increase sensitivity and specificity. The first validation phase analyzes the initial biomarker panel in independent samples, leading to a refined set often consisting of 50 to 100 candidates. Meta-analyses improve the sensitivity and specificity of the initial candidate set, integrating results from different, often publicly available datasets. Horizontal approaches investigate the same molecular platform in different organs \[[@B7]-[@B10]\], and vertical meta-analyses involve integration between different platforms, as in proteogenomic studies \[[@B11]-[@B13]\]. The advantages of meta-analyses are increased sample sizes and reduced experimental work, which help to increase the specificity and sensitivity of the initial biomarker. For example, a putative gene-based fingerprint in peripheral blood for kidney transplant tolerance was identified using this approach \[[@B14]\]. Information from the statistical analysis of microarrays (SAM) and predictive analysis of microarray (PAM) techniques identified an initial biomarker set, which was then cross-validated in independent samples and further refined in sample data from different microarray platforms \[[@B15]\].

However, the comparability of data from different laboratories has to be ensured and different laboratory procedures, inter-center variations and array performance on different days and when performed by different people have to be corrected for. For this purpose, the microarray quality control (MAQC) studies \[[@B16],[@B17]\] were initiated. These consisted of two phases aiming to provide quality control tools, develop data analysis guidelines and assess limitations and capabilities of various predictive biomarker models. As a result, common practices for the development and validation of microarray-based classifier models were defined and guidelines for global gene expression analysis established. A third phase is underway, focusing on next-generation sequencing techniques.

After the initial validation and refinement, the biomarker panel needs to undergo prospective validation in the clinical setting to establish the sensitivity, specificity and negative and positive predictive values for clinical application. The organizational challenges and expense of conducting prospective observational or interventional studies on biomarkers are reflected by the fact that, so far, only few studies have reached this status in the biomarker development process \[[@B5],[@B18],[@B19]\]. Increased numbers of patients and samples need to be investigated for a long period, often for a minimum of 2 years, before clinically relevant conclusions can be made. These studies require skilled staff and financial resources as well as sufficient laboratory infrastructure. Most importantly, the health and safety of patients and transplant organs remain the first priority, and prospective studies often carry unpredicted risks.

Identifying confounders
=======================

Another step towards confirming the clinical usefulness of a biomarker is to identify and control for experimental confounders. Confounders include sample bias, technology bias and patient bias. A peripheral blood-based transcriptomic biomarker has the advantage of being minimally invasive and assessable on a frequent basis at reduced cost and risk compared to biopsied samples. Importantly, a peripheral transcriptomic biomarker might also be measurable early, when no or minimal allograft damage has taken place. However, most cellular components of peripheral blood respond quickly to exogenous stimuli, such as temperature changes or shear force, inducing changes in gene expression *ex vivo*. In this regard, a hypoxia-associated gene expression signature was detected in peripheral blood mononuclear cells (PBMCs) after delayed sample processing compared to immediate sample processing \[[@B20]\].

Different laboratory techniques for sample allocation and handling make comparison of results difficult, or even lead to controversial results \[[@B21]-[@B27]\]. This aspect becomes particularly important in multi-center studies or when using publicly available data from independently performed studies. Therefore, safe, quick and easy handling during sample procurement must be ensured to minimize the overall impact of *ex vivo*changes to gene expression. Currently there are no uniform sample procurement guidelines. Several studies have been addressing this issue \[[@B20],[@B28],[@B29]\].

The complex composition of samples useable for non-invasive tests, such as blood and urine, make the identification of valid biomarkers difficult. For example, the abundant presence of globin mRNA as well as the heterogeneous nature of blood are important internal confounding factors to be controlled for when trying to identify a blood-based biomarker. Globin mRNA leads to decreased percentage present calls, decreased call concordance and increased signal variation when analyzing whole-blood gene expression profiles by microarray. Debey *et al*. \[[@B30]\] presented a method of combined whole-blood RNA stabilization and globin mRNA reduction followed by genome-wide transcriptome analysis. We also reported \[[@B31]\] the interference of globin mRNA when using whole blood for the discovery of peripheral biomarkers of acute renal allograft rejection. A comparison of four different protocols for total RNA preparation, amplification and synthesis of complementary RNA or cDNA and array hybridization revealed that only a combination of globin mRNA reduction during handling together with a mathematical algorithm provided depletion of globin mRNA expression. This approach improved the detection of biological differences between blood samples collected from patients with biopsy-proven AR or stable graft function \[[@B31]\].

Another obstacle in identifying a blood-based biomarker is the heterogeneity of blood. A typical blood sample contains a large number of cell types, each with its own distinct expression profile \[[@B32]\]. Heterogeneity is further compounded by the frequency of the same cell type being different between individuals \[[@B33]\]. Consequently, a differential expression profile observed in whole blood between two phenotypes could be caused by either a change in frequency of a specific type of cell without a change in the expression profiles of each cell type or a change in the expression profile of a cell type while the frequency of the cell type remains constant. Although one way to address this issue is to isolate subsets of specific cell types (for example, using cytometry or laser capture microdissection) and profile them, such techniques are expensive, time consuming and limited by difficulties in obtaining sufficient purified tissue with adequate RNA, and they may affect cell physiology and gene expression \[[@B20],[@B34]\]. To address these challenges, we and others have proposed several statistical approaches to deconvoluting gene expression profiles from heterogeneous tissues \[[@B35]-[@B37]\]. Using a deconvolution approach, we showed \[[@B35]\] that although whole-blood expression profiles did not reveal differential expression between patients with AR and those with stable transplant function, cell-type-specific expression profiles estimated by deconvolution of microarray data identified dramatic changes in two cell types that would have otherwise been completely missed. Differentially expressed genes in AR and stable transplant patients at a false discovery rate of 0.05 were identified between lymphocytes and neutrophils, as well as 137 upregulated genes in monocytes from the AR patients.

Laboratory test-based biomarkers in transplantation medicine
============================================================

Currently, a match between the human leukocyte antigen (HLA) in the sera of the donor and the recipient is the best pre-transplant biomarker \[[@B38]\]. Yet even in the case of a total match, the risk of clinical or subclinical AR and or CAD cannot be excluded. Post-transplant biomarkers include functional parameters that are mainly measured at the protein level, such as serum creatinine. The current gold standard to differentially diagnose allograft pathologies is the histological assessment of invasive graft biopsies. The threshold indicating allograft damage by current post-transplant biomarkers is high and reached at a point when significant damage has already occurred (Figure [2](#F2){ref-type="fig"}). Therefore, biomarkers for predicting the risk of damage or for indicating preclinical damage at the molecular level are needed. Applications that require an invasive biopsy limit the clinical applicability of identified biomarkers, and functional monitoring assays that use non-invasive samples, such as peripheral blood or patient urine, are more favorable (for patients and economically).

![**Biomarkers in transplantation medicine**. The application of biomarkers in transplantation medicine is very sensitive to time. Allograft damage progresses with time after transplantation, and the earlier allograft damage is detected, the better the chances for long-term allograft function become. Transplantation is the process that initiates the changes that lead to allograft damage. Post-transplantation biomarkers are dynamic, and the current post-transplantation biomarkers have a high threshold, allowing clinical diagnoses only long after transplantation damage, when changes are clinically and histologically manifested. Novel post-transplantation biomarkers require high sensitivity and a low threshold to indicate allograft damage pre-clinically; examples include non-invasive transcriptomic or proteomic biomarkers that will be applied to diagnose pathologies, to predict rejection, functional outcome, or the individual patient\'s response to immunossupression. Other applications include targets for novel therapeutic interventions New pre-transplantation biomarkers are stable and are needed to indicate a patient\'s baseline risk for damage or graft accommodation after transplantation. New pre-transplantation biomarkers are also needed to predict graft rejection and/or accommodation or the response to immunosuppression.](gm253-2){#F2}

Pre-transplantation biomarkers
------------------------------

Genomic analysis of donor and recipient peripheral blood DNA before transplantation has identified SNPs that indicate the risk or severity of allograft damage or predict allograft survival, and these markers are useful at the pre-transplantation stage \[[@B39]\]. Mutations in the innate immune system protein Toll-like receptor in donor and/or recipient blood were associated with reduced risk and severity of allograft rejection in liver, lung and kidney transplantation \[[@B40]-[@B45]\], and complement factor C3 mutations were predictive for renal allograft survival \[[@B46]\], further supporting the relevance of innate immunity for transplantation outcome. However, the success of SNP-based studies is often hindered by the need for large numbers of samples. Using samples across multiple centers might overcome this problem but results in inter-center variation. This variation has been successfully overcome by using statistical approaches, and a biomarker panel of ten SNPs for predicting AR was identified (Table [1a](#T1){ref-type="table"}). Pre-transplantation transcriptome analyses have shown significant differences in C3 gene expression between living and deceased donors, and these differences were directly related to the length of cold ischemia. Cold ischemia during transplantation begins with the perfusion of the graft after procurement, which decreases the organ temperature due to the absence of blood supply and creates an environment of hypoxia. Cold ischemia for living donor transplantation was significantly shorter than that for deceased donor transplantation, and changes in C3 gene expression correlated with 2-year graft function \[[@B47]\].

###### 

Laboratory-based biomarkers

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                      Organ                        Sample                                              Proposed mechanism                                                                                                         Biomarker                                                                      References
  ------------------------------------------------------------------- ---------------------------- --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------
  **(a)**Pre-transplantation biomarkers                                                                                                                                                                                                                                                                                                                          

                                                                      Kidney, lung, liver          Blood (DNA)                                         Genetic variants in donor/recipient are associated with risk and severity of AR and with allograft survival                15 SNPs, TLR, C3                                                               \[[@B39]-[@B44],[@B46]\]

                                                                      Kidney                       Biopsy (mRNA)                                       Expression profiles of innate immunity-related genes predict allograft survival                                            C3                                                                             \[[@B47]\]

                                                                      Kidney                       Serum (protein); biopsy (mRNA)                      Novel immunogenic epitopes                                                                                                 Non-HLA antigens                                                               \[[@B12],[@B48]-[@B50]\]

  **(b)**Post-transplantation biomarkers: acute allograft rejection                                                                                                                                                                                                                                                                                              

                                                                      Kidney                       Blood (PBMCs, mRNA), urine (mRNA)                   Cytotoxic proteins indicate AR                                                                                             FasL, GranzymeB, Perforine                                                     \[[@B27],[@B54],[@B57],[@B58]\]

                                                                      Kidney, lung, liver, heart   Blood (PBMCs), serum, BALF, urine (mRNA, protein)   Donor/recipient cytokine expression predicts/detects AR                                                                    CXCR, CXCL10 CXCL9                                                             \[[@B59]-[@B63]\]

                                                                      Kidney                       Biopsy, blood (PBMCs, mRNA)                         Alterations in miRNA are associated with AR                                                                                miR-142-5p, miR-155, miR-223                                                   \[[@B64]-[@B67]\]

                                                                      Kidney                       Biopsy                                              Biomarkers for antibody-mediated rejection (diagnostic/predictive)                                                         CD38, endothelial cell genes                                                   \[[@B70],[@B71]\]

                                                                      Kidney                       Biopsy, serum (protein)                             Antibodies against novel non-HLA antigens (diagnostic/predictive)                                                          AT1R-AA, MICA, Duffy, Kidd, Agrin                                              \[[@B50],[@B72]-[@B75]\]

                                                                      Kidney, heart                Biopsy, serum (mRNA, protein)                       Integrative proteogenomic biomarkers predict and diagnose AR across organs                                                 Novel non-HLA antigen PECAM1                                                   \[[@B12],[@B76]\]

  Post-transplantation biomarkers: chronic allograft damage                                                                                                                                                                                                                                                                                                      

                                                                      Kidney                       Blood (mRNA), biopsy (mRNA), urine (mRNA)           Predictive peripheral genes and proteins for mild/moderate chronic allograft damage and chronic antibody-mediated damage   TRIB1, CCL2                                                                    \[[@B13],[@B77],[@B82]\]

                                                                      Kidney, heart                Blood (protein), biopsy (mRNA), urine (protein)     Early diagnostic peripheral and urinary gene expression for IF/TA and anti-fibrotic target                                 KIM-1, CTGF                                                                    \[[@B78],[@B79],[@B85],[@B86]\]

  Post-transplantation biomarkers: graft accommodation                                                                                                                                                                                                                                                                                                           

                                                                      Liver, kidney                Blood (PBMCs, mRNA)                                 Peripheral gene expression identifies transplant recipients for discontinuation of immunosuppression                       \(a\) Three classifiers of 2,3 and 7 genes; (b) 33-gene panel; (c) 343 genes   \[[@B88],[@B89]\]

                                                                      Kidney                       Blood (mRNA)                                        B-lymphocyte-related gene signature of tolerance in transplant patient PBMCs                                               \(a\) B-cell signature\                                                        \[[@B90],[@B91]\]
                                                                                                                                                                                                                                                                                  (IGKV1D-13, IGKV4-1, IGLL1);\                                                  
                                                                                                                                                                                                                                                                                  (b) B-cell signature, ratio of FOXP3/α-1,2-mannosidase                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AT1R-AA, agonistic antibodies against angiotensin type II receptor 1; BALF, bronchoalveolar fluid; CCL, CC chemokine ligand; FasL, Fas ligand; FOXP3, Forkhead box P3; IGKV, immunoglobulin kappa variable group; IGLL1, immunoglobulin lambda-like polypeptide 1; KIM-1, kidney injury molecule 1; TLR, Toll-like receptor; IF/TA, interstitial fibrosis/tubular atrophy.

###### 

FDA-approved biomarkers

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Organ                        Sample                Proposed mechanism                                                                                                                  Biomarker                                             References
  ---------------------------- --------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ---------------------------
  Heart                        Blood (PBMCs, mRNA)   Gene-expression-based diagnostic score distinguishes stable from acute heart allograft rejection patients and mild from severe AR   AlloMap\                                              \[[@B92],[@B93]\]
                                                                                                                                                                                         (11-gene panel)                                       

  Heart, liver, lung, kidney   Serum (protein)       T-cell activation status indicates risk of AR, under-/over-immunosuppression                                                        ImmuKnow (T-cell-stimulation-dependent iATP levels)   \[[@B18],[@B97]-[@B100]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

More recently, the detection of novel antigens located in allograft tissue that drive allograft damage has been another means to predict AR before the development of corresponding antibodies in the serum. Integrative proteogenomic analyses have identified tissue-specific novel non-HLAs that led to serological responses in renal transplant patients. Antibodies against MHC class I polypeptide related sequence A (MICA) in the recipients that recognized antigens specific to the renal pelvis and the renal cortex were identified \[[@B12]\]. The association of such novel non-HLA antigens with clinically relevant phenotypes could identify specific immunogenic epitopes in AR and CAD \[[@B12],[@B48]-[@B50]\].

Post-transplantation biomarkers
-------------------------------

Transplantation initiates the processes responsible for AR and CAD (Figure [2](#F2){ref-type="fig"}). Biomarkers of different subtypes of rejection injury in the graft itself that indicate damage at the molecular level are needed and could help distinguish rejection episodes with high versus low probability of full functional recovery after anti-rejection therapy \[[@B51]\]. Similarly, biomarkers for graft accommodation could lead to reduction of immunosuppressive drugs or identification of novel drug targets.

Biomarkers of acute allograft rejection
=======================================

Advances in immunosuppressive therapy and improved patient monitoring have decreased the incidence of AR in solid organ transplantation. However, the lack of non-invasive biomarkers makes early diagnosis and optimized treatment regimens difficult, leading to approximately 10 to 30% of all transplant patients being diagnosed and treated for AR episodes within the first year after transplantation \[[@B52],[@B53]\], on top of a high number of undetected subclinical episodes. AR represents a major risk factor for long-term allograft dysfunction.

Among the first non-invasive, gene-expression-based cellular AR biomarkers discovered were the lethal chemokine perforine, tumor necrosis factor α, transmembrane protein Fas ligand and the serine protease granzyme B, proteins involved in cytotoxic lymphocyte function \[[@B27],[@B54]\] (Table [1a](#T1){ref-type="table"}). Several whole-genome transcriptional studies using PBMCs or urine specimens from transplant patients showed that expression of these genes indicated cell-mediated AR. However, the results could not always be confirmed in gene expression studies using graft biopsies or geographically distinct sample sets. In addition, the differential expression of these potential markers in other renal diseases limited their feasibility as AR-specific biomarkers in kidney transplantation \[[@B21]-[@B23],[@B55]\]. Only urinary cell transcriptional levels of perforin, granzyme B \[[@B56]\] and granulysin \[[@B57]\] were found to be diagnostic of biopsy-proven cell-mediated AR in renal transplant patients \[[@B58]\].

Other extensively studied potential biomarkers across liver, lung, kidney and heart transplants include chemokines and cytokines. These molecules lead to the differentiation, migration and proliferation of immune cells during AR. In this regard, the chemokines CXCL9 and CXCL10 and the chemokine receptor CXCR3 have been identified as potential biomarkers to predict AR and can be assessed in transplant patient serum, peripheral blood, urine and bronchoalveolar fluid. Other studies revealed their potential as novel therapeutic targets \[[@B59]-[@B63]\]. However, none of them has yet reached clinical trial status, and the relevance of these molecules needs to be determined in large cohort studies.

Other gene-expression-based AR biomarkers of increasing interest are miRNAs. These are small (about 19 to 25 nucleotides), naturally occurring noncoding RNAs that primarily repress the translation of mRNA or lead to its degradation \[[@B64]\]. miRNAs are potential biomarkers in renal transplant patient biopsies and stimulated PBMCs \[[@B65]\]. miR-155 has been found to be overexpressed in PBMCs from AR patients \[[@B65]\] and to enhance the development of inflammatory T cells \[[@B66]\]. miRNAs can influence AR, CAD and induction of tolerance \[[@B67]\].

Proteomic approaches identified urinary protein and peptide biomarkers that can correlate with AR. These studies provided a powerful means to distinguish for the first time between AR and BK virus nephropathy, two conditions that seem very similar when biopsied yet require opposing management strategies. A non-invasive urine-based test to distinguish between these entities is a major advance for the renal transplant field, especially with the increasing incidence of BK virus infection in transplant recipients \[[@B68],[@B69]\].

Antibody-mediated AR occurs in a minority of transplant patients and is characterized by the recipient\'s B lymphocytes forming antibodies against donor antigens. Current diagnosis is based on the presence of donor-specific antibodies in the periphery and on immunostaining for CD20 and peritubular deposition of complement-activated factor C4d. Recently, C4d-negative antibody-mediated AR episodes have been reported and asymptomatic episodes were associated with poor allograft outcome. This potentially leads to higher numbers of actual antibody-mediated AR cases when assessed retrospectively, further strengthening the necessity for new biomarkers of rejection. Endothelial cell gene expression in kidney transplant biopsies has been positively associated with the presence of antibody-mediated AR \[[@B70]\] and the presence of infiltrating clusters of CD38-positive plasmablasts, which correlated better with antibody-mediated rejection than with intragraft C4d staining \[[@B71]\].

Antibody-based biomarkers have been identified by investigating non-HLA antigen responses after transplantation, which have a greater role in allograft outcome than previously thought and thus represent novel diagnostic and predictive biomarkers. Of note are the agonistic antibodies against the angiotensin II type 1 receptor (AT1R-AA) described in renal allograft recipients with severe vascular types of AR \[[@B72]\]. Antagonistic antibodies against MICA, the chemokine receptor Duffy, Kidd polymorphic blood group antigens and the most abundant heparin sulfate proteoglycan, Agrin, were associated with decreased allograft survival \[[@B50],[@B73]\], chronic allograft damage \[[@B74]\] and the development of glomerulopathy \[[@B75]\].

In an integrative approach using transcriptomic and proteomic data, novel non-HLA antigens were identified as triggering *de novo*serological responses after transplantation in renal transplant recipients \[[@B12]\]. Interestingly, the antigens with the highest immunogenic power were located in the renal pelvis of the allograft. In another integrative study, genes coding for serum- and urine-detectable proteins that were differentially expressed in renal and cardiac biopsies from AR patients were tested for their potential as diagnostic protein biomarkers in a cross-organ, cross-platform study. Upregulated platelet endothelial cell adhesion molecule 1 (PECAM1) in biopsies, serum and urine identified renal AR with 89% sensitivity and 75% specificity in a cross-organ study using publicly available microarray data \[[@B76]\].

Biomarkers for chronic allograft injury
=======================================

In contrast to AR, chronic allograft injury is a slow progressive disorder involving complex multistage molecular processes, which can be seen from gradual, accumulative changes that lead to declining allograft function after 1 year post-transplantation and finally often result in allograft loss. These processes remain poorly understood and studies are hampered by the slow rate of changes that only slowly reveal a measurable phenotype, and by increasing post-transplantation external biases introduced by immunosuppressive treatment, associated side-effects, patient compliance, lifestyles and subclinical processes, often resulting in inconclusive findings. As a result, biomarkers, and especially non-invasive biomarkers specific for chronic allograft injury, are sparse, and extremely sensitive methods are needed to detect relevant changes before they accumulate and become clinically detectable.

Non-invasive markers of CAD, including urinary and peripheral biomarkers, could not only be readily identified and validated at numerous time-points but would also allow regular monitoring over a long period of time at low cost and would be associated with low patient risk. In an attempt to correlate blood expression signatures with biopsy-proven chronic allograft damage, gene expression panels were identified that predicted mild and moderate/severe chronic allograft damage, and Tribbles-1 (TRIB1) was identified to predict chronic antibody-mediated rejection \[[@B13],[@B77]\]. Well studied molecules in the pathogenesis of fibrosis, as seen in chronic allograft damage, are the transforming and connective tissue growth factors (transforming growth factor-β and connective tissue growth factor (CTGF)) \[[@B78],[@B79]\]. CTGF was increased in transplant patient urine before histopathological and functional chronic dysfunction, revealing it as a potential early non-invasive biomarker \[[@B80]\] and as a potential antifibrotic target \[[@B81]\]. Urinary expression of the chemokine CCL2 at 6 months post-transplantation predicted the development of chronic allograft dysfunction at 24 months post-transplantation in 111 patients \[[@B82]\]. Kidney injury molecule 1 (KIM1), previously discovered as a proximal tubular biomarker of acute kidney injury \[[@B83],[@B84]\], was associated with chronic allograft damage, including calcineurin inhibitor toxicity and interstitial fibrosis/tubular atrophy \[[@B85],[@B86]\]. However, KIM1 expression also correlated with transplant-independent drug-induced nephrotoxicity \[[@B87]\] and renal cell carcinoma \[[@B84]\], revealing it as a marker of general renal injury \[[@B83]\].

Biomarkers for monitoring graft accommodation
=============================================

Achieving an immunosuppression-free state, referred to as clinical operational tolerance, is the ultimate goal in transplantation. Current estimates report only 100 cases of clinical operational tolerance in renal transplants so far \[[@B88]\] and tolerance induction protocols, such as perioperative infusion of donor bone-marrow-derived stem cells or perioperative lymphocyte depletion, have failed and have led to graft loss in most cases. Specific biomarkers indicating immune quiescence and representing targets for novel tolerance induction protocols are needed. In a recent study \[[@B89]\], three gene-expression-based classifiers were identified, predicting liver tolerance and identifying liver transplant recipients for discontinuation of immunosuppression. Here, a combined approach of microarray discovery and quantitative reverse transcriptase (qRT)-PCR validation using PBMCs from a total of 44 tolerant and 48 non-tolerant patients was used \[[@B89]\] to determine a first gene expression signature of renal allograft tolerance consisting of 33 genes. This panel was able to predict the presence of a peripheral tolerant phenotype suggesting a pattern of reduced co-stimulatory signaling, immune quiescence, apoptosis and memory T cell responses \[[@B14]\].

Recently, two groups identified tolerance gene expression signatures in kidney transplant patients associated with B cells by applying the same microarray and qRT-PCR approach \[[@B90],[@B91]\]. Genes identified by Newell *et al*. \[[@B90]\] were associated with clinical and phenotypic parameters and with increased expression of multiple B-cell differentiation genes. The tolerance signature identified by Sagoo *et al*. \[[@B91]\] was also related to B cells, consisting of ten individual genes with a high ratio of the forkhead box protein FOXP3 to α-1,2-mannosidase. Tolerant patients showed an expansion of peripheral blood B and natural killer lymphocytes, fewer activated CD4^+^T cells, a lack of donor-specific antibodies and donor-specific hyporesponsiveness of CD4^+^T cells. Similar studies on operational tolerance have also been done in liver transplant recipients \[[@B89]\]. Tolerance-associated gene-expression signatures seem to be promising, as validation studies have proven their relevance. Whether these signatures can be used to predict or monitor tolerance in transplant patients has to be assessed in prospective studies using larger numbers of patients, which will be difficult given the low incidence of tolerance.

FDA-approved biomarkers
=======================

A transcriptomic analysis of peripheral blood samples from heart allograft patients identified an 11-gene panel that discriminated patients with stable allograft function from patients with moderate or severe AR \[[@B92]\], which led to the development of the first FDA-approved non-invasive diagnostic test for acute heart allograft rejection (AlloMap, XDx). Applying a mathematical algorithm, gene expression was translated into a diagnostic score \[[@B93]\] that discriminated stable transplants from AR and mild from severe AR. Another approach has exploited the measurement of the ATP release that depends on T-cell stimulation (iATP) \[[@B94]-[@B96]\], hypothesizing that the activation status of T cells indicates patients at high risk of acute rejection or at high risk for over- or under-immunosuppression. The iATP levels led to the development of a therapeutic response assay, ImmuKnow (Cylex) \[[@B18],[@B97]-[@B100]\]. Nevertheless, a new set of biomarkers is desperately needed to replace or complement these tests in order to improve clinical practice with regard to the function of transplanted organs. This will be achieved only with a biomarker panel - gene- or protein-based - that has high positive predictive value for injury (which is missing in the AlloMap panel) and has very high specificity and sensitivity for injury (which is missing in the Cylex test).

Conclusions
===========

The ultimate goal of biomarker studies in transplantation is to find non-invasive biomarkers of transplant pathologies using patient urine or blood that indicate changes at the molecular level, before the development of a clinical phenotype, that predict allograft outcome or response to therapy, and that possibly reveal novel targets for therapeutic interventions. As a result of the technological advances in high-throughput methodologies, multiple biomarker studies have been performed, leading to numerous potential biomarkers being published. However, only very few have graduated from the laboratory and gained FDA approval.

Laboratory-dependent confounding factors include differences in sample processing and data analyses, making comparability of data difficult. Regulatory elements and analytical guidelines, as suggested by the NIH or the MACQ studies, have been introduced to increase the validity and robustness of identified biomarkers and to make studies more homogenous. Sample-dependent confounding factors, such as the abundance of globin mRNA in whole blood, have been identified and successfully overcome, and advances in analytical methods now allow horizontal and vertical meta-analyses.

Promising non-invasive biomarkers for acute rejection and operational tolerance have therefore been identified and now need prospective validation in large patient cohorts. Multi-center studies have been introduced: the US \'Clinical Trials in Organ Transplantation\' (CTOT and CTOTC), the Canadian \'Biomarkers in Transplantation\' (BIT) project and the European study of \'Reprogramming the Immune System for Establishment of Tolerance\' (RISET).

In addition, we have gained deeper knowledge about the underlying pathogenic mechanisms of AR and CAD. The detection of novel non-HLA antibodies, C4d-negative antibody-mediated rejection, and the role of the innate immune system in acute rejection, as seen in the relevance of complement-system-associated molecules, will further biomarker development.

As seen for drug development studies, biomarker development studies need to become more uniform and standardized. Standard operating procedures for sample handling, experimental procedures and performance of data analyses need to be introduced, in addition to requirements for sample sizes, number and kind of validation studies.

Once transferred to the clinic, these recent advances will eventually lead to personalized transplantation medicine, including improved donor-recipient matching, individual immunosuppressive regimens, and individual risk assessment for AR or CAD and prediction of graft accommodation. These improvements will undoubtedly reduce the costs of health care dramatically. Finally, these changes will be reflected by increased allograft survival and decreased patient morbidity.
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